X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2845) 2845
Publication (126) 126
Newspaper Article (21) 21
Book / eBook (16) 16
Newsletter (16) 16
Book Review (15) 15
Magazine Article (10) 10
Dissertation (5) 5
Web Resource (4) 4
Book Chapter (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1724) 1724
anticoagulants (1171) 1171
anticoagulants - therapeutic use (952) 952
female (676) 676
male (644) 644
aged (453) 453
middle aged (429) 429
anticoagulants - adverse effects (419) 419
index medicus (409) 409
adult (360) 360
anticoagulants - administration & dosage (324) 324
medicine, general & internal (323) 323
risk factors (321) 321
thrombosis (221) 221
atrial fibrillation (200) 200
warfarin (184) 184
aged, 80 and over (182) 182
administration, oral (159) 159
thromboembolism (147) 147
hematology (143) 143
medicine & public health (142) 142
stroke (139) 139
heparin - therapeutic use (138) 138
treatment outcome (138) 138
hemorrhage - chemically induced (137) 137
venous thromboembolism (136) 136
time factors (128) 128
fibrinolytic agents - therapeutic use (119) 119
heparin (112) 112
atrial fibrillation - drug therapy (110) 110
risk (110) 110
anticoagulants - pharmacology (109) 109
internal medicine (109) 109
oral anticoagulants (109) 109
pregnancy (108) 108
prevention (108) 108
management (107) 107
medicine (107) 107
animals (105) 105
thromboembolism - prevention & control (105) 105
therapy (99) 99
dabigatran (98) 98
atrial fibrillation - complications (94) 94
rivaroxaban (94) 94
drug therapy (93) 93
heparin, low-molecular-weight - therapeutic use (93) 93
prospective studies (93) 93
patients (91) 91
vitamin k - antagonists & inhibitors (91) 91
analysis (86) 86
peripheral vascular disease (85) 85
venous thrombosis - drug therapy (84) 84
surgery (81) 81
platelet aggregation inhibitors - therapeutic use (79) 79
recurrence (79) 79
adolescent (77) 77
mortality (77) 77
pulmonary embolism (77) 77
anticoagulantes (76) 76
research (75) 75
care and treatment (73) 73
bleeding (72) 72
international normalized ratio (72) 72
warfarin - administration & dosage (72) 72
cardiac & cardiovascular systems (71) 71
pulmonary embolism - drug therapy (71) 71
aspirin - therapeutic use (70) 70
follow-up studies (70) 70
prognosis (70) 70
retrospective studies (70) 70
warfarin - therapeutic use (70) 70
health aspects (68) 68
anticoagulation (67) 67
warfarin - adverse effects (67) 67
stroke - prevention & control (65) 65
hemorrhage (64) 64
thrombosis - drug therapy (62) 62
atrial-fibrillation (61) 61
venous thrombosis (61) 61
prevalence (60) 60
risk assessment (58) 58
age factors (57) 57
myocardial infarction - drug therapy (56) 56
risk-factors (56) 56
hypertension (55) 55
clinical trials as topic (54) 54
venous thrombosis - etiology (53) 53
practice guidelines as topic (52) 52
diagnosis (51) 51
heparin - adverse effects (51) 51
randomized controlled trials as topic (51) 51
tomography, x-ray computed (51) 51
venous thromboembolism - prevention & control (51) 51
anticoagulant (50) 50
apixaban (50) 50
cancer (50) 50
direct oral anticoagulants (50) 50
incidence (50) 50
molecular-weight heparin (50) 50
venous thrombosis - prevention & control (50) 50
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1211) 1211
Spanish (707) 707
French (407) 407
Italian (172) 172
Swedish (140) 140
Norwegian (123) 123
Portuguese (123) 123
Romanian (41) 41
Lithuanian (16) 16
Czech (6) 6
German (6) 6
Japanese (5) 5
Bosnian (1) 1
Croatian (1) 1
Estonian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Jornal Vascular Brasileiro, ISSN 1677-5449, 2017, Volume 16, Issue 2, pp. 140 - 149
Resumo A síndrome antifosfolipíde (SAF) é uma doença autoimune sistêmica caracterizada por trombose arterial ou venosa recorrente e/ou morbidade gestacional e... 
Autoimmunity | Anticardiolipin antibodies | Thrombosis | Antiphospholipid syndrome | Lupus anticoagulant | SURGERY | PERIPHERAL VASCULAR DISEASE | CARDIAC & CARDIOVASCULAR SYSTEMS
Journal Article
Jornal Vascular Brasileiro, ISSN 1677-5449, 2017, Volume 16, Issue 2, pp. 140 - 149
A síndrome antifosfolipíde (SAF) é uma doença autoimune sistêmica caracterizada por trombose arterial ou venosa recorrente e/ou morbidade gestacional e pela... 
Artigo De Revisão | síndrome antifosfolípide | anticoagulante do lúpus | anticorpos anticardiolipina | trombose | autoimunidade
Journal Article
ISSN 0731-7085, 12/2017
Interaction thermodynamics between warfarin, a very popular anticoagulant, and Sudlow I binding siteof human (HSA) or bovine (BSA) serum albumin have been... 
Capillary electrophoresis | Electroforesi capil·lar | Anticoagulants (Medicine) | Anticoagulants (Medicina)
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 11, pp. 1016 - 1027
This study compared administration of the antiplatelet agent ticagrelor in the ambulance with administration in the cath lab in patients with ST-segment... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | GLYCOPROTEIN IIB/IIIA INHIBITORS | CLOPIDOGREL | MANAGEMENT | INITIATION | PLATELET INHIBITION | DOUBLE-BLIND | IIB-IIIA INHIBITORS | PRASUGREL | PRIMARY ANGIOPLASTY | Myocardial Infarction - mortality | Purinergic P2Y Receptor Antagonists - administration & dosage | Humans | Middle Aged | Male | Purinergic P2Y Receptor Antagonists - adverse effects | Adenosine - adverse effects | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Drug Therapy, Combination | Myocardial Infarction - diagnosis | Double-Blind Method | Time-to-Treatment | Anticoagulants - therapeutic use | Electrocardiography - drug effects | Adenosine - administration & dosage | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Coronary Angiography | Myocardial Infarction - drug therapy | Myocardial Reperfusion | Adenosine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Emergency Medical Services | Administration | Care and treatment | Hospitals | Research | Management | Heart attack | Risk factors | Myocardial infarction | Heart attacks | Catheterization | Angiography | Clinical trials | Patients | Thrombosis | Thrombolysis | Bleeding | Clinical outcomes | Studies | Reperfusion | Blood platelets | Coronary vessels | Implants | Intubation | Acute coronary syndromes | Drug therapy | Infart de miocardi | Adenosine | Malalties coronàries | Anticoagulants (Medicine) | Anticoagulants (Medicina) | Adenosina | Coronary diseases | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2011, Volume 365, Issue 23, pp. 2167 - 2177
In this clinical trial of hospitalized medically ill patients, extended thromboprophylaxis (30 days) with apixaban had similar efficacy to that of a shorter... 
REPLACEMENT | MEDICINE, GENERAL & INTERNAL | VENOUS THROMBOEMBOLISM | PULMONARY-EMBOLISM | DOUBLE-BLIND | PREVENTION | PLACEBO-CONTROLLED TRIAL | Pulmonary Embolism - prevention & control | Pyrazoles - therapeutic use | Venous Thromboembolism - mortality | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thromboembolism - epidemiology | Pyrazoles - adverse effects | Acute Disease | Double-Blind Method | Drug Administration Schedule | Hemorrhage - epidemiology | Risk Factors | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Treatment Outcome | Hospitalization | Anticoagulants - adverse effects | Heart Failure - drug therapy | Pulmonary Embolism - mortality | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Respiratory Insufficiency - drug therapy | Drugs | Enoxaparin | Dosage and administration | Venous thrombosis | Product/Service Evaluations | Thrombolytic drugs | Comparative analysis | Drug therapy | Heart failure | Fees & charges | Anticoagulants | Compression | Prophylaxis | Congestive heart failure | Thrombosis | Bleeding | Embolism | Compression therapy | Ultrasonic imaging | Hospitals | Ultrasonography | Safety | Thromboembolism | Health risk assessment | Respiratory Insufficiency | Hemorrhage | Life Sciences | Venous Thromboembolism | Heart Failure | Pyrazoles | Pyridones | Human health and pathology | Pulmonary Embolism
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2006, Volume 355, Issue 21, pp. 2203 - 2216
In this trial, patients with acute coronary syndromes undergoing an early invasive approach were randomly assigned to treatment with heparin or enoxaparin plus... 
MEDICINE, GENERAL & INTERNAL | INHIBITION | MYOCARDIAL-INFARCTION | REPLACE-2 RANDOMIZED-TRIAL | STRATEGY | PLATELET GLYCOPROTEIN-IIB/IIIA | UNSTABLE ANGINA | ST-SEGMENT ELEVATION | BLOCKADE | INTERVENTION | UNFRACTIONATED HEPARIN | Recombinant Proteins - therapeutic use | Humans | Middle Aged | Heparin - therapeutic use | Male | Enoxaparin - therapeutic use | Recombinant Proteins - adverse effects | Angioplasty, Balloon, Coronary | Angina, Unstable - drug therapy | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | Myocardial Ischemia - epidemiology | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Hirudins - adverse effects | Angina, Unstable - therapy | Coronary Artery Bypass | Aged | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Hemorrhage - chemically induced | Aggregation | Evaluation | Blood platelets | Drug therapy | Coronary heart disease | Heart attacks | Medical imaging | Mortality | Informed consent | Clinical medicine | Angina pectoris | Acute coronary syndromes | Health education | Patients | Bypass cardiopulmonar | Bypass cardiopulmonary | Malalties coronàries | Anticoagulants (Medicine) | Heparin | Heparina | Anticoagulants (Medicina) | Coronary diseases
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2006, Volume 354, Issue 14, pp. 1464 - 1476
Unfractionated heparin and low-molecular-weight heparins are often used to treat acute coronary syndromes. In this study, the pentasaccharide fondaparinux was... 
MEDICINE, GENERAL & INTERNAL | METAANALYSIS | MANAGEMENT | MYOCARDIAL-INFARCTION | TASK-FORCE | AMERICAN-COLLEGE | ELEVATION | OUTCOMES | UNFRACTIONATED HEPARIN | Polysaccharides - therapeutic use | Recurrence | Myocardial Infarction - mortality | Stroke | Humans | Middle Aged | Angina, Unstable - mortality | Polysaccharides - adverse effects | Anticoagulants - therapeutic use | Male | Treatment Outcome | Enoxaparin - therapeutic use | Anticoagulants - adverse effects | Enoxaparin - adverse effects | Angioplasty, Balloon, Coronary | Myocardial Infarction - therapy | Myocardial Infarction - drug therapy | Angina, Unstable - drug therapy | Survival Analysis | Angina, Unstable - therapy | Female | Aged | Hemorrhage - chemically induced | Medical research | Heart attacks | Drug therapy | Angina pectoris | Tonsillitis | Myocardial infarction | Infart de miocardi | Polysaccharides | Amigdalitis | Ús terapèutic | Polisacàrids | Anticoagulants (Medicine) | Anticoagulants (Medicina) | Therapeutic use | Myocardial Infarction/drug therapy/mortality/therapy | Enoxaparin/adverse effects/therapeutic use | Medical and Health Sciences | Medicin och hälsovetenskap | Angioplasty; Transluminal; Percutaneous Coronary | Polysaccharides/adverse effects/therapeutic use | MEDICINE | Hemorrhage/chemically induced | Angina; Unstable/drug therapy/mortality/therapy | MEDICIN | Cerebrovascular Accident | Anticoagulants/adverse effects/therapeutic use
Journal Article
Journal Article
ISSN 0028-4793, 02/2014
Mehta et al. do not show any significant difference between early and delayed intervention in patients with acute coronary syndrome. In their study, 9.9% of... 
Cardiovascular pharmacology | Farmacologia cardiovascular | Malalties coronàries | Anticoagulants (Medicine) | Heparin | Heparina | Anticoagulants (Medicina) | Coronary diseases
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 05/2015, Volume 13, Issue 5, pp. 775 - 781
Journal Article